WEBULL
News
BDSX
7.68
-10.13%
-0.87
Biodesix To Present Data On Development Of New Ultra-Sensitive ESR1 Test For Initial Detection And Monitoring Of Mutations In HR+/HER2- Advanced Breast Cancers At SABCS
Benzinga · 4d ago
Biodesix To Present New Findings On Its On-Market Nodify Lung Tests, With Data Highlighting Importance Of Lung Nodule Risk Classification To Support Early Detection Of Lung Cancer, At 2025 NACLC
Benzinga · 4d ago
Biodesix to Present New Data at Two Major Upcoming Scientific Meetings
Barchart · 4d ago
Weekly Report: what happened at BDSX last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at BDSX last week (1117-1121)?
Weekly Report · 11/24 10:23
Weekly Report: what happened at BDSX last week (1110-1114)?
Weekly Report · 11/17 10:23
Weekly Report: what happened at BDSX last week (1103-1107)?
Weekly Report · 11/10 10:20
Biodesix, Inc. at Risk: How a Federal Shutdown Could Disrupt Revenue and Growth
TipRanks · 11/05 06:02
Biodesix, Inc. Reports Strong Q3 Growth and Optimistic Outlook
TipRanks · 11/05 00:18
Biodesix (BDSX) Gets a Buy from Lake Street
TipRanks · 11/04 14:35
Cautious Optimism: Biodesix’s Strong Performance Amid Cash Runway and Profitability Concerns
TipRanks · 11/04 10:15
Biotech Earnings Spark After-Hours Surge: TCMD, BDSX, EXAS Lead The Charge
NASDAQ · 11/04 04:58
Biodesix Reports Strong Q3 2025 Revenue Growth
TipRanks · 11/04 03:56
Biodesix raises 2025 revenue guidance to $84M-$86M as primary care expansion accelerates
Seeking Alpha · 11/04 03:46
Biodesix reports Q3 EPS ($1.16), consensus ($1.51)
TipRanks · 11/03 21:21
Biodesix raises FY25 revenue view to $84M-$86M from $80M-$85M, consensus $83.24M
TipRanks · 11/03 21:20
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 11/03 21:12
Biodesix Q3 revenue beats estimates on development services business growth 
Reuters · 11/03 21:11
Biodesix GAAP EPS of -$1.16 beats by $0.35, revenue of $21.8M beats by $0.82M
Seeking Alpha · 11/03 21:10
Biodesix Raises FY2025 Sales Guidance from $80.000M-$85.000M to $84.000M-$86.000M vs $83.236M Est
Benzinga · 11/03 21:04
More
Webull provides a variety of real-time BDSX stock news. You can receive the latest news about BIODESIX INC through multiple platforms. This information may help you make smarter investment decisions.
About BDSX
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.